Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4783294 | 1.00 | CYP2D6 (0.45) | CYP2D6KCNH2ATMTDP1MEN1 | |
| SCHEMBL4739479 | 0.88 | CYP2D6 (0.59) | CYP2D6KCNH2 | |
| SCHEMBL4739471 | 0.88 | CYP2D6 (0.59) | CYP2D6KCNH2 | |
| SCHEMBL4741167 | 0.79 | CYP2D6 (0.47) | CYP2D6KCNH2 | |
| SCHEMBL4741164 | 0.79 | CYP2D6 (0.47) | CYP2D6KCNH2 | |
| SCHEMBL10332110 | 0.77 | KMT2A (0.54) | ATMTDP1MEN1KMT2APOLB | |
| SCHEMBL4742049 | 0.77 | CYP2D6 (0.49) | CYP2D6KCNH2 | |
| SCHEMBL4742045 | 0.77 | CYP2D6 (0.49) | CYP2D6KCNH2 | |
| SCHEMBL24205546 | 0.76 | MEN1 (0.55) | ATMTDP1MEN1KMT2APOLB | |
| SCHEMBL5024804 | 0.76 | MEN1 (0.55) | ATMTDP1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242174-B2 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2012-06-21 | — | — | US | disclosed |
| WO-2008094592-A1 | HYDROXAMIC ACID DERIVATIVES OF ANILINE USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARNA, LLC (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | ANTXR2, AGXT, AADAC | CYP2D6 941/4885KCNH2 3164/4885ATM 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.